Interferon beta-1a

Generic Name: Interferon beta-1a

Brand Names: Avonex, Rebif

Drug Type: Biotech

CAS Number: 145258-61-3

Unique Ingredient Identifier: XRO4566Q4R

Background: Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta.

Indication: For treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum

Associated Conditions: Relapsing Multiple Sclerosis (RMS)

Clinical Trials

Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS

Withdrawn

Conditions: Multiple Sclerosis

Interventions: Drug: Rebif (IFN β-1a subcutaneous three times per week)
Drug: Tecifdera (dimethyl fumarate)

First Posted Date: 2015-04-17

Last Posted Date: 2016-02-29

Lead Sponsor: Brigham and Women's Hospital

Registration Number: NCT02419638

Locations: 🇺🇸
Partners MS Center, 1 Brookline Place Suite 225, Brookline, Massachusetts, United States

Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis

Phase 1

Conditions: Relapsing-remitting Multiple Sclerosis

Interventions: Drug: Rebif®
Drug: Avonex

First Posted Date: 2015-02-18

Last Posted Date: 2016-06-03

Lead Sponsor: PD Dr. Marcus Müller

Target Recruit Count: 50

Registration Number: NCT02364986

Locations: 🇩🇪
Department of Neurology, Bonn, Germany
🇩🇪
Phase I Unit, Bonn, Germany

Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Rebif
Drug: Avonex
Drug: BCD-054

First Posted Date: 2015-02-10

Last Posted Date: 2017-04-10

Lead Sponsor: Biocad

Target Recruit Count: 60

Registration Number: NCT02359877

Locations: 🇷🇺
OOO "BioEk", Saint-Petersburg, Russian Federation

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

Phase 3

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Interferon beta-1a
Drug: Ozanimod
Drug: Placebo to ozanimod
Drug: Placebo to interferon beta-1a

First Posted Date: 2014-11-19

Last Posted Date: 2020-11-25

Lead Sponsor: Celgene

Target Recruit Count: 1346

Registration Number: NCT02294058

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Neurological Research Institute Inc, Columbus, Ohio, United States
🇺🇸
The Polyclinic, Seattle, Washington, United States

and more 220 locations

Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers

Phase 1

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: peginterferon beta-1a
Drug: Rebif

First Posted Date: 2014-10-21

Last Posted Date: 2015-02-02

Lead Sponsor: Biogen

Target Recruit Count: 30

Registration Number: NCT02269930

Locations: 🇺🇸
Research Site, Evansville, Indiana, United States

Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™

Phase 4

Completed

Conditions: Relapsing Multiple Sclerosis
Clinically Isolated Syndrome

Interventions: Drug: Rebif

First Posted Date: 2014-10-01

Last Posted Date: 2018-03-30

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 106

Registration Number: NCT02254304

Locations: 🇩🇪
Please contact the Merck KGaA Communication Center, Darmstadt, Germany

RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate

Phase 4

Terminated

Conditions: Multiple Sclerosis

Interventions: Drug: Rebif®

First Posted Date: 2014-04-17

Last Posted Date: 2017-01-23

Lead Sponsor: EMD Serono

Target Recruit Count: 1

Registration Number: NCT02117050

Locations: 🇺🇸
Call EMD Serono Medical Information for information on recruiting sites, Boston, Massachusetts, United States

A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis

Phase 4

Completed

Conditions: Multiple Sclerosis, Relapsing-Remitting

Interventions: Drug: Rebif®

First Posted Date: 2014-02-17

Last Posted Date: 2018-09-20

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 200

Registration Number: NCT02064816

Locations: 🇩🇪
Please contact the Merck KGaA Communication Center, Darmstadt, Germany

Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis

Phase 3

Completed

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: Ozanimod placebo
Drug: Ozanimod
Drug: Interferon beta-1a placebo
Drug: Interferon beta-1a

First Posted Date: 2014-01-28

Last Posted Date: 2021-02-11

Lead Sponsor: Celgene

Target Recruit Count: 1320

Registration Number: NCT02047734

Locations: 🇺🇸
Neurostudies Inc, Port Charlotte, Florida, United States
🇵🇱
RESMEDICA Spolka z o.o., Kielce, Poland
🇵🇱
Receptos Study Site 402, Olsztyn, Poland

and more 296 locations

A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Phase 3

Withdrawn

Conditions: Relapsing Remitting Multiple Sclerosis

Interventions: Drug: Laquinimod
Drug: Avonex®

First Posted Date: 2013-11-03

Last Posted Date: 2021-11-09

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Registration Number: NCT01975298

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy